EANS-News: Intercell Recognized by U.S. Department of Defense for Development of Japanese Encephalitis Vaccine, IXIARO®
Vienna (Austria)/Washington (USA), May 25, 2010 (euro adhoc) -
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.
Company Information
Intercell AG (VSE: ICLL) has been honored in a ceremony at the Pentagon today for the company´s role in the development of Japanese encephalitis vaccine, IXIARO®. The Commanding General, United States Army Medical Research and Materiel Command (USAMRMC), the Acting Secretary of Defense for Health Affairs (HA) and Gerd Zettlmeissl, chief executive officer of Intercell, commented on the excellent collaborative efforts between the Department of Defense (DoD) and Intercell that lead to the development and subsequent commercialization for IXIARO. Senior DoD officials also expressed their appreciation to Intercell for making a next-generation JE vaccine available for use by Service members. As a result of this public-private effort, military personnel, dependants, and civilian travelers will be protected against the serious and growing risk of disease caused by the JE virus when deployed or traveling to many countries of the world.
Gerd Zettlmeissl commented, "We are extremely honored to be recognized by the DoD for our collaborative research and development efforts. Special recognition is given to our colleagues at Walter Reed Army Institute of Research (WRAIR) who initiated this JE vaccine project in the mid 1990s and contributed to numerous aspects of the development program up to licensure."
IXIARO was developed under a Collaborative Research and Development Agreement (CRADA) with WRAIR and approved in March 2009 by the U.S. Food and Drug Administration for the prevention of Japanese Encephalitis. Intercell currently distributes and markets IXIARO to the U.S. military, with Novartis Vaccines USA marketing and distributing the vaccine to the private market in the U.S.
Japanese Encephalitis is a mosquito-borne infection that strikes approximately 50,000 persons per year and is most common in developing countries in Asia, including India and China.
end of announcement euro adhoc
Further inquiry note:
Intercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com
Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market